Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus KENALOG 80.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus KENALOG 80.
KENALOG IN ORABASE vs KENALOG-80
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, immunosuppressive, and anti-proliferative effects. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, which reduces prostaglandin and leukotriene synthesis. It also suppresses cytokine production and immune cell migration.
Adjunctive treatment for inflammatory and ulcerative diseases of oral mucosa (e.g., aphthous ulcers, lichen planus)Topical corticosteroid for oral lesions
Intra-articular and soft tissue administration for inflammatory and rheumatic conditions (e.g., osteoarthritis, rheumatoid arthritis, bursitis, tendinitis)Intralesional use for dermatologic conditions (e.g., keloids, hypertrophic scars, lichen planus, psoriasis plaques)Allergic and inflammatory ocular disorders (e.g., conjunctivitis, keratitis)Endocrine disorders (e.g., adrenal insufficiency in combination with mineralocorticoids)Off-label: Treatment of cystic acne, alopecia areata, and prevention of post-burn contractures
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
60 mg (1.5 mL) intramuscularly (deep IM) as a single dose for allergic/ inflammatory conditions; intra-articular or soft tissue injection: 10-40 mg for large joints, 5-25 mg for medium joints, 2.5-10 mg for small joints; intralesional: up to 1 mg per injection site, repeated as needed.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Terminal elimination half-life: 2–4 hours for triamcinolone acetonide; prolonged in hepatic impairment (up to 6–8 hours).
Hepatic metabolism primarily via CYP3A4; undergoes reduction, oxidation, and conjugation.
Primarily hepatic via CYP3A4-mediated metabolism. Triamcinolone acetonide is metabolized to 6β-hydroxy and 20-dihydro metabolites, which are then conjugated and excreted renally.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Primarily hepatic metabolism followed by renal excretion of inactive metabolites; less than 5% excreted unchanged in urine, with minor biliary/fecal elimination (<2%).
Approximately 70-90% bound to corticosteroid-binding globulin and albumin.
Approximately 68% bound to albumin and corticosteroid-binding globulin (CBG).
Estimated Vd of 1.5-3.5 L/kg, reflecting extensive tissue distribution.
Vd: 1.4 L/kg, indicating extensive tissue distribution (higher than plasma volume).
Systemic bioavailability via oral mucosa is low but not precisely quantified; local delivery is the primary route.
Intramuscular: 100% (complete); Oral: approximately 23% (low due to first-pass metabolism); Topical: variable (<1% systemic unless applied to compromised skin).
No dose adjustment required for renal impairment.
No specific GFR-based dose adjustments available; use with caution in severe renal impairment due to potential fluid retention and hypertension.
No dose adjustment required for hepatic impairment.
No specific Child-Pugh based adjustments; caution in severe hepatic impairment due to increased risk of adverse effects.
Safety and efficacy in pediatric patients have not been established; use only if clearly needed and use the smallest effective amount.
Not recommended for children under 12 years due to potential growth suppression; for children 12 years and older, similar to adult dosing based on severity and condition, typically 0.6-1.7 mg/kg/day in divided doses; adjust according to response.
Use the smallest effective amount for the shortest duration due to increased potential for systemic effects with age.
Use lowest effective dose due to increased risk of osteoporosis, hypertension, and diabetes; monitor blood pressure, blood glucose, and bone density; typical adult dose but with cautious titration.
No FDA black box warning.
Intrathecal administration is contraindicated and can result in severe neurologic events including arachnoiditis, meningitis, paraparesis, and sensory disturbances. Systemic corticosteroids have been associated with increased risk of infection and potential for hypothalamic-pituitary-adrenal (HPA) axis suppression.
["Immunosuppression may increase susceptibility to infections","Adrenal suppression with prolonged use","Avoid use in patients with known hypersensitivity to corticosteroids","Use with caution in patients with diabetes, hypertension, or osteoporosis","Do not swallow or apply to large areas of skin"]
["HPA axis suppression with prolonged use or high doses; taper dose gradually","Increased susceptibility to infections; avoid live vaccines","Masking of infection signs; monitor for active infections","Osteoporosis risk with long-term use","Ocular effects: cataracts, glaucoma, central serous chorioretinopathy","Gastrointestinal perforation risk in patients with diverticulitis, peptic ulcer, or recent bowel anastomosis","Cardiovascular effects: hypertension, fluid retention, congestive heart failure","Musculoskeletal: myopathy, tendon rupture, avascular necrosis","Psychiatric disturbances: euphoria, insomnia, mood swings, psychosis","Growth suppression in children"]
["Systemic fungal infections","Hypersensitivity to triamcinolone or any component of the formulation","Viral or bacterial infections of the oral mucosa (e.g., herpes simplex)"]
["Systemic fungal infections","Intrathecal administration","Known hypersensitivity to triamcinolone acetonide or any component of the formulation","Administration into unstable joints, infected areas, or injection sites with septic arthritis","Live or attenuated virus vaccines in immunocompromised patients (relative)"]
Data Pending Review
Data Pending Review
Avoid hot, spicy, or acidic foods during treatment as they may irritate the lesion. No specific food-drug interactions are known.
No specific food interactions reported. However, because corticosteroids can increase blood glucose, advise patients with diabetes to monitor glucose levels closely after injection and adjust diet/insulin as needed. Avoid excessive salt intake if fluid retention or hypertension is a concern.
Triamcinolone acetonide (KENALOG IN ORABASE) is a corticosteroid. Systemic absorption from oral mucosal application is minimal but may occur. In first trimester, corticosteroid use is associated with a small increased risk of oral clefts (odds ratio ~1.3-3.4). Second and third trimester use may cause fetal adrenal suppression, intrauterine growth restriction, and preterm birth if significant systemic exposure occurs. Topical use with minimal absorption is generally considered low risk, but theoretical risks persist.
Triamcinolone acetonide (KENALOG-80) is a corticosteroid. First trimester: associated with a small increased risk of oral clefts (odds ratio ~1.3-3.4) in some studies; also linked to intrauterine growth restriction (IUGR). Second/Third trimester: chronic use may cause fetal adrenal suppression, IUGR, and premature birth. Benefits must outweigh risks.
Triamcinolone acetonide is excreted into human breast milk in low amounts following systemic administration. The milk-to-plasma ratio is unknown for topical oral formulation, but due to low systemic absorption, concentrations are expected to be negligible. No adverse effects on the infant have been reported with topical corticosteroids. Caution is advised with prolonged or extensive use.
Triamcinolone acetonide is excreted into breast milk in low amounts; M/P ratio not established. At single low doses, amounts are negligible. High-dose or chronic use could potentially suppress neonatal adrenal function or cause other effects. Caution advised.
No specific dose adjustment needed for standard use of KENALOG IN ORABASE during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) are not clinically relevant due to minimal systemic absorption. Avoid excessive application or use on large mucosal areas to minimize systemic exposure.
Triamcinolone pharmacokinetics in pregnancy may be altered due to increased volume of distribution and clearance. However, no specific dose adjustment guidelines exist. Use lowest effective dose for shortest duration. For respiratory indications, inhaled/budesonide preferred; for systemic use, prednisolone may be preferred due to placental metabolism.
Category C
Category C
Apply a thin layer to the lesion after meals and at bedtime. Do not rub in; allow to form a film. Avoid use on infected lesions unless antifungal/antibacterial coverage is provided. Use with caution in patients with diabetes, hypertension, or peptic ulcer disease due to potential systemic absorption.
Kenalog-80 (triamcinolone acetonide injectable suspension 80 mg/mL) is a high-potency, long-acting corticosteroid used for intra-articular, intrabursal, or intradermal injection. Avoid intravascular injection due to risk of embolic phenomena. Do not use for intravenous, intramuscular, or subcutaneous administration. Shake well before use. Use a tuberculin syringe for precise dosing in small joints. Monitor for signs of joint infection post-injection. Contraindicated in systemic fungal infections and in patients with idiopathic thrombocytopenic purpura.
Apply a thin layer to the affected area after meals and at bedtime.Do not rub or massage the paste into the tissue.Avoid eating or drinking immediately after application to allow the paste to adhere.Do not use if you have a fungal or bacterial infection in the mouth unless directed.Notify your doctor if symptoms persist beyond 7 days or if swelling occurs.
This medication is injected directly into a joint or soft tissue to reduce inflammation and pain.Do not overuse the treated joint for at least 48 hours after injection to allow the medication to work and reduce risk of injury.Common side effects include temporary pain or swelling at the injection site, facial flushing, and mood changes.Contact your doctor immediately if you experience signs of infection (fever, increased redness, warmth, or pain) or allergic reaction (rash, difficulty breathing).Inform your doctor about all other medications you take, especially blood thinners, NSAIDs, or other corticosteroids.This medication may raise blood sugar; monitor closely if you have diabetes.Do not receive any vaccines for 2 weeks before or after this injection without consulting your doctor.